Recent developments in CCR2 antagonists

Bibliography

• Tsutsumi C, Sonoda K, Egashira K, et al. The critical role of ocular- infiltrating macrophages in the development of choroidal neovascularization. J Leukoc Biol 2003;74:25-32
   PubMed Web of Science ®Google Scholar
• Conrad SM, Strauss-Ayali D, Field AE, et al. Leishmania-derived murine monocyte chemoattractant protein 1 enhances the recruitment of a restrictive population of CC chemokine receptor 2-positive macrophages. Infect Immun 2007;75:653-65
   PubMed Web of Science ®Google Scholar
• Boring L, Gosling J, Cleary M, et al. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394:894-7
   PubMed Web of Science ®Google Scholar
• Carulli MT, Ong VH, Ponticos M, et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum 2005;52:3772-82
   PubMed Web of Science ®Google Scholar
• Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006;116:115-24
   PubMed Web of Science ®Google Scholar
• Charo IF, Taubman MB. Chemokines in the pathogenesis of Vascular Disease. Circ Res 2004;95:858-66
   PubMed Web of Science ®Google Scholar
• Kitagawa K, Wada T, Furuichi K, et al. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol 2004;165:237-46
   PubMed Web of Science ®Google Scholar
• Dawson J, Miltz W, Mir AK, et al. Targeting monocyte chemoattractant protein-1 signalling in disease. Expert Opin Ther Targets 2003;7:35-48
   PubMed Web of Science ®Google Scholar
• Rollins BJ. Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today 1996;2:198-204
   PubMedGoogle Scholar
• Ogilvie P, Thelen S, Moepps B, et al. Unusual chemokine receptor antagonism involving a mitogen-activated protein kinase pathway. J Immunol 2004;172:6715-22
   Google Scholar
• Belvisi MG, Hele DJ, Birrell MA. New anti-inflammatory therapies and targets for asthma and chronic obstructive pulmonary disease. Expert Opin Ther Target 2004;8:265-85
   PubMed Web of Science ®Google Scholar
• Merck.Preparation of [(1R,3S)-3-isopropyl-3-[[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl]cyclopentyl][(3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl]amine salt as chemokine receptor CCR-2 antagonist. WO2005044795; 2005
   Google Scholar
• Yang L, Jiao RX, Moyes C, et al. Discovery of 3-piperidinyl-1-cyclopentanecarboxamide as a novel scaffold for highly potent CC chemokine receptor 2 antagonists. J Med Chem 2007;50:2609-11
   PubMed Web of Science ®Google Scholar
• Butora G, Jiao R, Parsons WH, et al. 3-Amino-1-alkyl-cyclopentane carboxamides as small molecule antagonists of the human and murine CC chemokine receptor 2. Bioorg Med Chem Lett 2007;17:3636-41
   PubMed Web of Science ®Google Scholar
• Janssen. Preparation of mercaptoimidazoles as CCR2 receptor antagonists. WO2005118578; 2005
   Google Scholar
• Janssen. Substituted dipiperidines as CCR2 antagonists, their preparation, pharmaceutical compositions, and use in therapy. US2006069123; 2006
   Google Scholar
• Janssen. Preparation of quaternary ammonium salts as chemoattractant cytokine receptor 2 antagonists. WO2006012135; 2006
   Google Scholar
• Janssen. Substituted cyclopentyl piperidine CCR2 antagonists for treatment of CCR2 -mediated inflammatory syndromes and disorders. WO2008109238; 2008
   Google Scholar
• Xia M, Hou C, DeMong DE, et al. Synthesis, structure-activity relationship and in vivo antiinflammatory efficacy of substituted dipiperidines as CCR2 antagonists. J Med Chem 2007;50:5561-3
   PubMed Web of Science ®Google Scholar
• Buntinx M, Hermans B, Goossens J, et al. Pharmacological profile of JNJ-27141491 [(S)-3-[(3,4-difluorophenyl)propyl]-5-isoxazol-5-yl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxyl acid methyl ester], as a noncompetitive and orally active antagonist of the human chemokine receptor CCR2. J Pharmacol Exp Ther 2008;327:1-9
   Google Scholar
• Incyte. Preparation of 3-cycloalkylaminopyrrolidine chemokine receptor antagonists as antiinflammatory and immunomodulatory bioactive compounds. WO2005060665; 2005
   Google Scholar
• Pfizer. Preparation of piperidinyl and piperazinyl 3-aminocyclopentanecarboxamides as modulators of chemokine receptors. US2006004018; 2006
   Google Scholar
• Brodmerkel C, Huber R, Covington M, et al. Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J Immunol 2005;175:5370-8
   PubMed Web of Science ®Google Scholar
• Carter PH, Brown GD, Friedrich SR, et al. Capped diaminopropionamide-glycine dipeptides are inhibitors of CC chemokine receptor 2 (CCR2 ). Bioorg Med Chem Lett 2007;17:5455-61
   PubMed Web of Science ®Google Scholar
• Cherney RJ, Mo R, Meyer DT, et al. Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists. J Med Chem 2008;51:721-4
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb. Preparation of pyrrolidin-2-one derivatives as chemokine receptor modulators. WO2008014360; 2008
   Google Scholar
• Novartis. Preparation of 1H-indole-2-carboxylic acid N-(piperidin-4-yl)amides and related derivatives as chemokine receptor, particularly CCR2 and CCR5 antagonists. WO2005077932; 2005
   Google Scholar
• Novartis. Preparation of N-piperidinylethylcyclohexyl indolecarboxamide derivatives as inhibitors of chemokine receptors or macrophage protein. WO2008101905; 2008
   Google Scholar
• ChemoCentryx. Preparation of aryl and heteroaryl sulfonamides as CCR2 antagonists. WO2006076644; 2006
   Google Scholar
• ChemoCentryx. Preparation of N-phenylbenzenesulfonamide derivatives as CCR2 inhibitors. WO2008008374; 2008
   Google Scholar
• ChemoCentryx. N-(Triazolylpyridinyl)-benzenesulfonamides as chemokine receptor antagonists, their preparation, pharmaceutical compositions, and use in therapy. WO2008008375; 2008
   Google Scholar
• Glaxo. Preparation of pyridinyl sulfonamide modulators of chemokine receptors. WO 2007067875; 2007
   Google Scholar
• Glaxo. Preparation of benzenesulfonamide inhibitors of CCR2 chemokine receptor. WO 2007014008; 2007
   Google Scholar
• Glaxo. Preparation of azolylmethylbenzenesulfonamides as CCR2 chemokine receptor antagonists. WO2007014054; 2007
   Google Scholar
• Angelini. Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition. WO2008061671; 2008
   Google Scholar
• Millennium. Preparation of pyrrolidinylazepans and pyrrolidinyloxepanes as antagonists of CCR2 chemokine receptors. WO2007053495; 2007
   Google Scholar
• Millennium. Preparation of bipyrrolidine and thienylpyrrolidine derivatives as antagonists of CCR2. WO2007053499; 2007
   Google Scholar
• Millennium. Preparation of pyrrolidinylpiperidines and related compounds as antagonists of chemokine CCR2 inhibitors. WO2007053498; 2007
   Google Scholar
• Abbott. Aminopyrrolidine derivatives as chemokine receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of autoimmune diseases. WO2008060621; 2008
   Google Scholar
• Astrazeneca AB. Piperazine derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use as antagonists of CC chemokines (CCR2b and CCR5) for the treatment of inflammatory diseases. WO2007071952; 2007
   Google Scholar
• Epix. Preparation of benzothiadiazine compounds and their use as chemokine receptor antagonists. WO2008045558; 2008
   Google Scholar
• Epix. Preparation of piperidinyl and pyrrolidinyl carboxamide compounds as chemokine receptor antagonists for treating diseases associated with monocyte, leukocyte, and lymphocyte accumulation. WO2008045564; 2008
   Google Scholar